Diabetes

Insulin Therapy & Delivery Technologies

Insulin Therapy & Delivery Technologies” will offer an in-depth exploration of the evolution and future direction of insulin use and its administration in diabetes care. Since the discovery of insulin over a century ago, it has remained a life-saving therapy for millions of individuals with Type 1 and advanced Type 2 diabetes. However, ongoing challenges such as optimal dosing, timing, patient adherence, and hypoglycemia risk have driven continuous innovation in both insulin formulations and delivery systems. Recent decades have seen the development of rapid-acting, long-acting, and ultra-long-acting insulin analogs, each designed to better mimic the body’s natural insulin patterns and improve glycemic control. These analogs have been instrumental in reducing fluctuations in blood glucose levels, lowering the incidence of severe hypoglycemia, and providing greater flexibility for patients. In addition to traditional subcutaneous injections, newer delivery options such as inhaled insulin, transdermal patches, and microneedle arrays are being explored for their potential to improve patient comfort and compliance. Research into glucose-responsive “smart insulin,” which activates only when needed based on blood glucose levels, is also underway and promises to revolutionize insulin therapy in the near future.